Neoadjuvant Cabazitaxel Plus Abiraterone/Leuprolide Acetate in High-Risk Prostate Cancer Patients: ACDC-RP Phase II Trial. Fleshner NE, Sayyid RK, Hansen AR, Chin JLK, et al. Clin Cancer Res 2023 Jul 13:CCR-23-0731. doi: 10.1158/1078-0432.CCR-23-0731.

Read + Share

Amedeo Smart

Independent Medical Education

Fleshner NE, Sayyid RK, Hansen AR, Chin JLK, et al. Neoadjuvant Cabazitaxel Plus Abiraterone/Leuprolide Acetate in High-Risk Prostate Cancer Patients: ACDC-RP Phase II Trial. Clin Cancer Res 2023 Jul 13:CCR-23-0731. doi: 10.1158/1078-0432.CCR-23-0731.
PMID: 37439809